Swiss Life Forecast, price target & analysts
Swiss Life Target price 2024 - Analyst rating & recommendation
Swiss Life Classifications & Recommendation:
Swiss Life Price Target
| Target Price | CHF655.92 |
| Price | CHF698.60 |
| Deviation | 6.11% |
| Number of Estimates | 12 |
| 12 Analysts have issued a price target Swiss Life 2025 . The average Swiss Life target price is CHF655.92. This is 6.11% lower than the current stock price. The highest price target is CHF732.00 4.78% , the lowest is CHF540.00 22.70% . | |
| A rating was issued by 15 analysts: 5 Analysts recommend Swiss Life to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Swiss Life stock has an average upside potential 2025 of 6.11% . Most analysts recommend the Swiss Life stock at Hold. |
Sales and Margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 15.24 | 16.83 |
| 25.15% | 10.44% | |
| Net Margin | 7.02% | 7.20% |
| 3.54% | 2.55% |
3 Analysts have issued a sales forecast Swiss Life 2024 . The average Swiss Life sales estimate is CHF16.8b . This is 9.17% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF20.8b 34.73% , the lowest is CHF9.2b 40.34% .
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | CHF15.2b | 25.15% |
|---|---|---|
| 2024 | CHF16.8b | 10.44% |
| 2025 | CHF17.3b | 2.91% |
| 2026 | CHF15.8b | 9.00% |
7 Swiss Life Analysts have issued a net profit forecast 2024. The average Swiss Life net profit estimate is CHF1.2b . This is 10.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF1.3b 16.57% , the lowest is CHF1.1b 5.11% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | CHF1.1b | 22.51% |
|---|---|---|
| 2024 | CHF1.2b | 13.25% |
| 2025 | CHF1.3b | 4.55% |
| 2026 | CHF1.3b | 2.68% |
Net Margin
| 2023 | 7.02% | 3.54% |
|---|---|---|
| 2024 | 7.20% | 2.55% |
| 2025 | 7.31% | 1.53% |
| 2026 | 8.25% | 12.86% |
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 37.12 | 42.04 |
| 22.51% | 13.25% | |
| P/E | 16.62 | |
| EV/Sales | 1.75 |
7 Analysts have issued a Swiss Life forecast for earnings per share. The average Swiss Life <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is CHF42.04 . This is 10.75% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is CHF44.25 16.57% , the lowest is CHF39.90 5.11% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | CHF37.12 | 22.51% |
|---|---|---|
| 2024 | CHF42.04 | 13.25% |
| 2025 | CHF43.95 | 4.54% |
| 2026 | CHF45.13 | 2.68% |
P/E ratio
| Current | 18.40 | 55.41% |
|---|---|---|
| 2024 | 16.62 | 9.67% |
| 2025 | 15.90 | 4.33% |
| 2026 | 15.48 | 2.64% |
Based on analysts' sales estimates for 2024, the Swiss Life stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 1.75 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 1.16 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.91 | 1.55% |
|---|---|---|
| 2024 | 1.75 | 8.64% |
| 2025 | 1.70 | 2.83% |
| 2026 | 1.86 | 9.89% |
P/S ratio
| Current | 1.27 | 7.20% |
|---|---|---|
| 2024 | 1.16 | 8.40% |
| 2025 | 1.13 | 2.83% |
| 2026 | 1.24 | 9.89% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
